The chief executive of French drug maker Sanofi SA, which last year acquired Genzyme Corp. of Cambridge, said Tuesday that his company has established a presence in the Boston area because of its innovation ecosystem.
Citing the area’s dense cluster of universities, hospitals, biotechnology start-ups, and venture capital firms, Christopher A. Viehbacher told Boston College’s Chief Executives’ Club of Boston that “I think the most fertile environment in the world today is right here in the Boston-Cambridge area.”
But he said there are risks to innovation, including budget cuts to the National Institutes of Health, rising health care costs, and the inability of big pharmaceutical companies to embrace the “disruptive element” of innovation.
To read the full, original article click on this link: Hub is the world’s ‘most fertile environment’ for biotech innovation, Sanofi chief says - The Boston Globe online
